肿瘤细胞治疗研究
FRONTIER PAPERS
Ultrasensitive In Vivo Imaging of Adoptive Immune Cell Distribution and Expansion Using Second Near-Infrared Conjugated Oligoelectrolyte Probes.
监测实体瘤中的过继性细胞治疗对于评估疗效和指导临床用药至关重要，但现有技术灵敏度差、背景信号高且会干扰治疗功能，使监测受到制约。
Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.
这些发现为靶向胶质母细胞瘤和其他实体瘤的多模式免疫治疗建立了一个有前景的平台。
Targeting the PSMD14-BCKDK pathway overcomes immune suppression and enhances CAR-NK infiltration in glioblastoma.
肿瘤细胞与免疫细胞之间的营养竞争是胶质母细胞瘤（GBM）微环境的标志性特征，但氨基酸代谢重编程与免疫逃逸的机制仍未完全阐明。
Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.
我们的研究结果表明，抑制 IL-10 分泌可增强 CAR 工程化 NK-92 细胞的治疗潜力，提示这一策略有望成为临床转化的有前景途径。
From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies.
免疫治疗，尤其是 CAR-T 细胞疗法，已经彻底改变了血液系统恶性肿瘤和自身免疫性疾病的治疗。
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.
嵌合抗原受体工程化 NK 细胞在过继性肿瘤免疫治疗中展现出前景。
Targeting the COX-2/PGE(2) axis to enhance NK and T cell immunotherapy in brain tumors.
侵袭性脑肿瘤如胶质母细胞瘤（GBM）仍然是最致命的人类癌症之一，尽管采用多模式治疗，中位生存期仅为 15 个月。
CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines.
嵌合抗原受体 (CAR) T 细胞疗法是一种有前景的抗癌免疫疗法。
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
颅内注射 HER2 靶向 CAR-NK 细胞在复发性 GB 患者中是可行且安全的。1 108 个 NK-92/5.28.z 细胞被确定为后续扩展队列重复局部注射 CAR-NK 细胞的最大可行剂量。
The Gut-Brain-Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities.
胶质瘤，尤其是胶质母细胞瘤，是最难治疗的一类癌症，原因在于其高度免疫抑制的肿瘤微环境（TME）以及血脑屏障的限制性。
MEMBER ACCOUNT
登录成功会直接打开下一页。
